معرفی
Nicole Renee Leboeuf, M.D. serves as an Associate Professor of Dermatology at Harvard Medical School, based at Brigham and Women's Hospital in Boston, Massachusetts. Her clinical and research work focuses on the intersection of dermatology and oncology, particularly examining immune-related adverse events from cancer immunotherapies and cutaneous manifestations of malignancies.
Dr. Leboeuf's research interests center on dermatologic toxicities from immune checkpoint inhibitors, with significant contributions to defining diagnostic criteria for D-irAEs through consensus-based disease definitions. Her work explores how cancer type and histology influence cutaneous immunotherapy toxicities, the timing of cutaneous immune-related adverse events and survival outcomes, and multi-organ immune-related adverse events and their implications. She has made important contributions to understanding cutaneous T-cell lymphoma and rare dermatologic conditions like blastic plasmacytoid dendritic cell neoplasm.
Her publication record demonstrates significant impact in the field, with numerous high-citation papers including a Nature publication on neoantigen vaccines for renal cell carcinoma. Her recent work (2024-2025) shows continued emphasis on improving the understanding and management of immune-related skin conditions in cancer patients, with studies examining geographic variations in adverse events, mortality outcomes related to dupilumab treatment, and consensus guidelines for managing EGFR inhibitor-related skin toxicities.
Dr. Leboeuf maintains extensive collaborative networks with researchers across multiple institutions, particularly working with colleagues like Kerry Reynolds, Yevgeniy Semenov, and Cecilia Larocca. Her work has been recognized through significant media coverage, with 113 news outlets picking up one of her highly-cited Nature publications, and substantial engagement on academic social media platforms.
Based at Brigham and Women's Hospital's Dermatology Department, Dr. Leboeuf contributes to both clinical care and research within one of Harvard Medical School's major teaching hospitals, addressing critical challenges in the rapidly evolving field of cancer immunotherapy and its dermatologic consequences.